GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Forward Rate of Return (Yacktman) %

Apollon Formularies (AQSE:APOL) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2021)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Apollon Formularies's forward rate of return for was 0.00%.

The historical rank and industry rank for Apollon Formularies's Forward Rate of Return (Yacktman) % or its related term are showing as below:

AQSE:APOL's Forward Rate of Return (Yacktman) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.43
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Apollon Formularies Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Apollon Formularies's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Forward Rate of Return (Yacktman) % Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apollon Formularies's Forward Rate of Return (Yacktman) %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Forward Rate of Return (Yacktman) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Forward Rate of Return (Yacktman) % falls into.



Apollon Formularies Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Apollon Formularies's Forward Rate of Return of Dec. 2021 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.0265+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Apollon Formularies Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 05-22-2015